Drug Trial Radar · NCT07211633
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)
Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
360
Planned (sponsor's estimate)
Start
Jul 9, 2025
Primary completion
Oct 31, 2026
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- TG Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 8, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the pharmacokinetics of ublituximab when administered subcutaneously (SC) compared to intravenous (IV) administration in participants with RMS.
Conditions
- Relapsing Multiple Sclerosis
Interventions
UblituximabBiological
Administered as an IV infusion.
UblituximabBiological
Administered as an SC injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area Under the Curve From Week 0 to Week 24 (AUC0-W24) of UblituximabTime frame: Up to Week 24
Locations
48 sites in 9 countries. Site status is shown where the registry gives one.
TG Therapeutics Investigational Trial Site
Banja Luka, Bosnia and Herzegovina
TG Therapeutics Investigational Trial Site
Bihać, Bosnia and Herzegovina
TG Therapeutics Investigational Trial Site
Mostar, Bosnia and Herzegovina
TG Therapeutics Investigational Trial Site
Saravejo, Bosnia and Herzegovina
TG Therapeutics Investigational Trial Site
Tulza, Bosnia and Herzegovina
TG Therapeutics Investigational Trial Site
Pleven, Bulgaria
TG Therapeutics Investigational Trial Site
Plovdiv, Bulgaria
TG Therapeutics Investigational Trial Site
Sofia, Bulgaria
TG Therapeutics Investigational Trial Site
Sofia, Bulgaria
TG Therapeutics Investigational Trial Site
Veliko Tarnovo, Bulgaria
TG Therapeutics Investigational Trial Site
Varaždin, Croatia
TG Therapeutics Investigational Trial Site
Zagreb, Croatia
TG Therapeutics Investigational Trial Site
Brno, Czechia
TG Therapeutics Investigational Trial Site
Hradec Králové, Czechia
TG Therapeutics Investigational Trial Site
Jihlava, Czechia
TG Therapeutics Investigational Trial Site
Ostrava, Czechia
TG Therapeutics Investigational Trial Site
Pardubice, Czechia
TG Therapeutics Investigational Trial Site
Zlín, Czechia
TG Therapeutics Investigational Trial Site
Tbilisi, Georgia
TG Therapeutics Investigational Trial Site
Tbilisi, Georgia
TG Therapeutics Investigational Trial Site
Tbilisi, Georgia
TG Therapeutics Investigational Trial Site
Tbilisi, Georgia
TG Therapeutics Investigational Trial Site
Tbilisi, Georgia
TG Therapeutics Investigational Trial Site
Tbilisi, Georgia
TG Therapeutics Investigational Trial Site
Tbilisi, Georgia
TG Therapeutics Investigational Trial Site
Tbilisi, Georgia
TG Therapeutics Investigational Trial Site
Budapest, Hungary
TG Therapeutics Investigational Trial Site
Budapest, Hungary
TG Therapeutics Investigational Trial Site
Budapest, Hungary
TG Therapeutics Investigational Trial Site
Kaposvár, Hungary
TG Therapeutics Investigational Trial Site
Kistarsca, Hungary
TG Therapeutics Investigational Trial Site
Pécs, Hungary
TG Therapeutics Investigational Trial Site
Shtip, North Macedonia
TG Therapeutics Investigational Trial Site
Skopje, North Macedonia
TG Therapeutics Investigational Trial Site
Kragujevac, Serbia
TG Therapeutics Investigational Trial Site
Niš, Serbia
TG Therapeutics Investigational Trial Site
Cherkasy, Ukraine
TG Therapeutics Investigational Trial Site
Ivano-Frankivsk, Ukraine
TG Therapeutics Investigational Trial Site
Ivano-Frankivsk, Ukraine
TG Therapeutics Investigational Trial Site
Ivano-Frankivsk, Ukraine
Showing 40 of 48 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.